MARKET

CELC

CELC

Celcuity
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.29
+0.79
+3.85%
Closed 16:00 07/29 EDT
OPEN
20.99
PREV CLOSE
20.50
HIGH
22.37
LOW
20.99
VOLUME
66.53K
TURNOVER
--
52 WEEK HIGH
33.01
52 WEEK LOW
5.00
MARKET CAP
309.51M
P/E (TTM)
-22.2769
1D
5D
1M
3M
1Y
5Y
Cowen initiates Celcuity with an outperform rating on breast cancer diagnostic
Cowen has initiated shares of Celcuity (CELC +6.2%) with an overweight rating but no price target. The company is developing a companion diagnostic, CELsignia, for breast cancer. CELsignia uses live
Seekingalpha · 14h ago
--Cowen Initiates Coverage on Celcuity With Outperform Rating
MT Newswires · 1d ago
--Needham Starts Celcuity at Buy With $50 Price Target
MT Newswires · 2d ago
Celcuity to Participate in the William Blair Biotech Focus Conference
MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in t...
ACCESSWIRE · 07/08 20:15
Where Do Hedge Funds Stand On Celcuity Inc. (CELC)?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to ...
Insider Monkey · 06/30 13:06
Technology and Healthcare names dominate midday movers
Gainers: BSQUARE Corporation (BSQR) +99%.Cerevel Therapeutics Holdings (CERE) +94%.Marin Software Incorporated (MRIN) +73%.Exela Technologies (XELA) +43%.Weidai (WEI) +39%.Infobird (IFBD) +36%.Powerbridge Technologies (PBTS) +31%.Auddia (AUUD) +23%.Amesite...
Seekingalpha · 06/29 16:34
Cerevel Therapeutics, Avinger leads healthcare gainers; DiaMedica Therapeutics, MediWound among major losers
Gainers: Cerevel Therapeutics CERE +113%, Avinger (AVGR) +22%, Translate Bio TBIO +14%, Orphazyme ORPH +11%, Regional Health Properties (RHE) +8%.Losers: DiaMedica Therapeutics DMAC -33%, MediWound MDWD -29%, ReShape Lifesciences RSLS -24%, Celcuity (CELC)...
Seekingalpha · 06/29 15:00
Iovance Biotherapeutics, Purple Innovation among premarket losers' pack
DiaMedica Therapeutics DMAC -27% after announcing mixed results for kidney disease therapy in mid-stage study.Celcuity CELC -18% after raises $56M capital via equity offering.Purple Innovation PRPL -12% after lowering Q2 guidance due to production challeng...
Seekingalpha · 06/29 12:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CELC. Analyze the recent business situations of Celcuity through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CELC stock price target is 36.67 with a high estimate of 50.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 65
Institutional Holdings: 3.27M
% Owned: 22.52%
Shares Outstanding: 14.54M
TypeInstitutionsShares
Increased
13
258.36K
New
11
956.16K
Decreased
4
12.79K
Sold Out
1
1.00K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Brian Sullivan
Co-Founder/Chief Scientific Officer/Vice President/Secretary/Director
Lance Laing
Chief Financial Officer
Vicky Hahne
Independent Director
Richard Buller
Independent Director
David Dalvey
Independent Director
Leo Furcht
Independent Director
Richard Nigon
No Data
About CELC
Celcuity, Inc. is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it. CELx platform provides traditional molecular diagnostics, which provides a snapshot of the genetic mutations present in a patient’s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival.

Webull offers kinds of Celcuity Inc stock information, including NASDAQ:CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.